Login / Signup

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.

Sangjin ShinChan Mi ParkHanbyeol KwonKyung-Hun Lee
Published in: BMC cancer (2016)
GEM-E for pancreatic cancer is not more effective than GEM in a real-world setting, and it does not provide reasonable cost-effectiveness over GEM.
Keyphrases
  • locally advanced
  • quality improvement
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • squamous cell carcinoma
  • emergency department
  • adverse drug
  • radiation therapy